KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.
The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.
We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.
Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:
- Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
- Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
- Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies
KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
The KMT MouseTM is your essential tool for therapeutics and vaccine development.
April 06 2016
Connect with KMT Hepatech representative at EASL meeting in Barcelona
April 03 2016
VP of Operations Mr. Kaz Fortuna attending BIO-Europe Spring conference in Stockholm early April
February 29 2016
15 years of in vivo services with proprietary KMT Mouse - uPA/SCID mouse model with stable human hepatocyte engraftment